Insmed Inc

NASDAQ:INSMUnited States

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Contact Information

Headquarters

700 Us Highway 202/206BRIDGEWATER, NJ, United States 08807

Phone

908-977-9900

Fax

---

Executives

Chairman of the Board, Chief Executive Officer

William Lewis

Chief Financial Officer

Sara Bonstein

Chief Operating Officer

Roger Adsett

Chief People Strategy Officer

S. Nicole Schaeffer

Chief Medical Officer

Martina Flammer